Centauri Therapeutics granted FDA QIDP status for CTX-187 treatment of Gram-negative bacterial infections
The recognition of the potential value of our technology further underpins our belief in its potential to transform treatment paradigms…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
